Dr Richard McClelland
Post-Doctoral Research Associate
Publications
2015
- Gee, J. M. et al. 2015. A new cell panel to study oestrogen receptor loss in acquired endocrine resistant breast cancer. Cancer Research 75(9), article number: P3-05-19.
2013
- Lazaro, G. et al. 2013. Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response. Endocrine Related Cancer 20(5), pp. 691-704. (10.1530/ERC-13-0019)
2012
- Stone, A. et al. 2012. Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. PLoS ONE 7(7), article number: e40466. (10.1371/journal.pone.0040466)
- White, A. W., Carpenter, N., Lottin, J. R. P., McClelland, R. and Nicholson, R. 2012. Synthesis and evaluation of novel anti-proliferative pyrroloazepinone and indoloazepinone oximes derived from the marine natural product hymenialdisine. European Journal of Medicinal Chemistry 56, pp. 246-253. (10.1016/j.ejmech.2012.08.022)
2011
- Hutcheson, I. R. et al. 2011. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Research 13(2), article number: R29. (10.1186/bcr2848)
- Gee, J. M. W. et al. 2011. Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance. Hormone Molecular Biology and Clinical Investigation 5(2), pp. 67-77. (10.1515/HMBCI.2011.009)
2009
- Elsheikh, S. E., Green, A. R., McClelland, R. A., Hutcheson, I. R., Gee, J. M. W., Nicholson, R. I. and Ellis, I. O. 2009. 162 Altered Histone Modifications and their regulating enzymes in Fulvestrant resistant breast cancer cell line In Vitro [Abstract]. Laboratory Investigation 89(S1), pp. 38A-39A. (10.1038/labinvest.2008.132)
- Gee, J. M. W. et al. 2009. The dark side of antihormonal action in breast cancer. In: Hiscox, S. E., Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer, pp. 63-84., (10.1007/978-1-4020-8526-0_4)
- Elsheikh, S. E., Green, A. R., McClelland, R. A., Hutcheson, I. R., Gee, J. M. W., Nicholson, R. I. and Ellis, I. O. 2009. Altered Histone Modifications and Their Regulating Enzymes in Fulvestrant Resistant Breast Cancer Cell Line In Vitro [Abstract]. Modern Pathology 22(S1), pp. 38A-39A., article number: 162. (10.1038/modpathol.2008.210)
2006
- Hutcheson, I. R. et al. 2006. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine-Related Cancer 13(S1), pp. S89-S97. (10.1677/erc.1.01279)
- Gee, J. M. W., Shaw, V. E., Hiscox, S. E., McClelland, R. A., Rushmere, N. K. and Nicholson, R. I. 2006. Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocrine-Related Cancer 13(S1), pp. S77-S88. (10.1677/erc.1.01274)
- Hiscox, S. E., Jordan, N. J., Jiang, W. G., Harper, M. E., McClelland, R., Smith, C. and Nicholson, R. 2006. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. Endocrine-Related Cancer 13(4), pp. 1085-1099. (10.1677/erc.1.01270)
- Burmi, R. S., McClelland, R. A., Barrow, D., Ellis, I. O., Robertson, J. F. R., Nicholson, R. I. and Gee, J. M. W. 2006. Microarray studies reveal novel genes associated with endocrine resistance in breast cancer [Abstract]. Breast Cancer Research 8(S2), article number: S11. (10.1186/bcr1554)
- Britton, D. J. et al. 2006. Bidirectional cross talk between ER alpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Research and Treatment 96(2), pp. 131-146. (10.1007/s10549-005-9070-2)
2005
- Yee, S. W. et al. 2005. Novel tetralone-derived retinoic acid metabolism blocking agents: synthesis and in vitro evaluation with liver microsomal and MCF-7 CYP26A1 cell assays. Journal of Medicinal Chemistry 48(23), pp. 7123-7131. (10.1021/jm0501681)
- Hiscox, S. E., Harper, M. E., Jiang, W. G., McClelland, R. and Nicholson, R. 2005. Elevated c-met expression accompanies endocrine resistance in MCF7 breast cancer cells and promotes in vitro cell migration and invasion. Breast Cancer Research and Treatment 94(Supp 1), pp. S161-S161.
2003
- Britton, D. J., Hutcheson, I. R., Barrow, D., McClelland, R. A., Gee, J. M. W. and Nicholson, R. I. 2003. Oestrogen receptor phosphorylation in hormone sensitive and anti-hormone resistant breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82(S1), pp. S61. (10.1023/A:1026252325164)
- Nicholson, R. I., Gee, J. M. W., Knowlden, J. M., McClelland, R. A., Madden, T., Barrow, D. and Hutcheson, I. R. 2003. The biology of antihormone failure in breast cancer. Breast Cancer Research and Treatment 80(S1), pp. 29-34. (10.1023/A:1025467500433)
2002
- Gee, J. M. W. et al. 2002. ZD1839 ('Iressa') improves the antitumour activity of tamoxifen ('Nolvadex') and ICI 182, 780 ('Faslodex') in antihormone responsive breast cancer [Abstract]. European Journal of Cancer 38(S7), pp. S59. (10.1016/S0959-8049(02)80835-8)
- Nicholson, R. I. et al. 2002. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. In: Castagnetta, L. et al. eds. Hormone-Related Tumors: Novel Approaches to Prevention and Treatment. Annals of the New York Academy of Sciences Vol. 963. New York: The New York Academy of Sciences, pp. 104-115., (10.1111/j.1749-6632.2002.tb04101.x)
2001
- Nicholson, R. I. et al. 2001. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocrine-Related Cancer 8(3), pp. 175-182. (10.1677/erc.0.0080175)
- McClelland, R. A. et al. 2001. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142(7), pp. 2776-2788. (10.1210/en.142.7.2776)
2000
- Madden, T., Barrow, D., McClelland, R. A., Gee, J. M. W. and Nicholson, R. I. 2000. Modulation of oestrogen action by receptor gene inhibition. European Journal of Cancer 36(S4), pp. 34-35. (10.1016/S0959-8049(00)00216-1)
1999
- Nicholson, R. I., McClelland, R. A., Robertson, J. F. R. and Gee, J. M. W. 1999. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocrine-Related Cancer 6(3), pp. 373-387. (10.1677/erc.0.0060373)
- McClelland, R. A., Gee, J. M. W., O'Sullivan, L. A., Barnes, D. M., Robertson, J. F. R., Ellis, I. O. and Nicholson, R. I. 1999. p21(WAF1) expression and endocrine response in breast cancer. Journal of Pathology 188(2), pp. 126-132. (10.1002/(SICI)1096-9896(199906)188:2<126::AID-PATH340>3.0.CO;2-O)
1998
- McClelland, R. A. et al. 1998. Oestrogen-regulated genes in breast cancer: association of pLIV1 with response to endocrine therapy. British Journal of Cancer 77(10), pp. 1653-1656. (10.1038/bjc.1998.457)
1997
- Knowlden, J. M. et al. 1997. Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens. Clinical Cancer Research 3(11), pp. 2165-2172.
1996
- McClelland, R. A., Gee, J. M. W., Francis, A. B., Robertson, J. F. R., Blamey, R. W., Wakeling, A. E. and Nicholson, R. I. 1996. Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. European Journal of Cancer 32(3), pp. 413-416. (10.1016/0959-8049(95)00517-X)
- Nicholson, R. I. et al. 1996. Pure antiestrogens - The most important advance in the endocrine therapy of breast cancer since 1896?. In: Castagnetta, L., Nenci, I. and Bradlow, H. L. eds. Basis for Cancer Management. Annals of the New York Academy of Sciences Vol. 784. New York: New York Academy of Sciences, pp. 325-335., (10.1111/j.1749-6632.1996.tb16247.x)
- McClelland, R. A. et al. 1996. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Research and Treatment 41(1), pp. 31-41. (10.1007/BF01807034)
1995
- Gee, J. M. W., Douglas-Jones, A. G., Hepburn, P., Sharma, A. K., McClelland, R. A., Ellis, I. O. and Nicholson, R. I. 1995. A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers. Journal of Pathology 177(3), pp. 285-293. (10.1002/path.1711770311)
- Nicholson, R. I., McClelland, R. A. and Gee, J. M. W. 1995. Steroid hormone receptors and their clinical significance in cancer. Journal of Clinical Pathology 48(10), pp. 890-895. (10.1136/jcp.48.10.890)
- Gee, J. M. W. et al. 1995. Immunocytochemical localization of fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. International Journal of Cancer 64(4), pp. 269-273. (10.1002/ijc.2910640410)
- Robertson, J. F. R., Gee, J. M. W., McClelland, R. A., Ellis, I. O., Willsher, P., Blamey, R. W. and Nicholson, R. I. 1995. BCL2 Expression In Breast-Cancer - Identification Of Patients Who Should Not Receive Endocrine Therapy [Abstract]. British Journal of Surgery 82(5), pp. 698. (10.1002/bjs.1800820540)
- Manning, D. L. et al. 1995. Differential expression of estrogen-regulated genes in breast-cancer. Acta Oncologica 34(5), pp. 641-646.
1994
- Gee, J. M. W. et al. 1994. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. International Journal of Cancer 59(5), pp. 619-628. (10.1002/ijc.2910590508)
- Nicholson, R. I. et al. 1994. Transforming growth factor-α and endocrine sensitivity in breast cancer. Cancer Research 54(7), pp. 1684-1689.
- Nicholson, R. I. et al. 1994. Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy. Breast Cancer Research and Treatment 29(1), pp. 117-125. (10.1007/BF00666187)
- Manning, D. L. et al. 1994. Oestrogen-regulated genes in breast cancer: Association of pLIV1 with lymph node involvement. European Journal of Cancer 30(5), pp. 675-678. (10.1016/0959-8049(94)90543-6)
- Nicholson, R. I., Francis, A. B., McClelland, R. A., Manning, D. L. and Gee, J. M. W. 1994. Pure anti-oestrogens (ICI 164384 and ICI 182780) and breast cancer: is the attainment of complete oestrogen withdrawal worthwhile?. Endocrine-Related Cancer 1(4), pp. 5-17. (10.1677/erc.0.0010005)
1993
- Manning, D. L., McClelland, R. A., Gee, J. M. W., Chan, C. M. W., Green, C. D., Blamey, R. M. and Nicholson, R. I. 1993. The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer. European Journal of Cancer 29(10), pp. 1462-1468. (10.1016/0959-8049(93)90021-7)